Drug profile · INN
trifarotene
AKLIEF
trifarotene (AKLIEF) is a retinoic acid receptor gamma agonist. Route of administration: topical. Current US regulatory status: approved.
Drug details — trifarotene
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
trifarotene (AKLIEF) is a retinoic acid receptor gamma agonist. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Retinoic acid receptor gamma agonist
Primary target: Retinoic acid receptor gamma
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trifarotene?
trifarotene (AKLIEF) is a retinoic acid receptor gamma agonist. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for trifarotene?
AKLIEF is a marketed brand name for trifarotene. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trifarotene?
trifarotene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.